TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
LENZ

LENZ Therapeutics Inc

Healthcare · Biotechnology

4.10$ -0.2% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns LENZ Therapeutics Inc (LENZ)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 58.5% of the shares are freely tradable; institutional investors hold 111.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 111.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 58.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 56.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 31Mio.

Largest Shareholders

Institutions

Institutions LENZ
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 13.30 4,178,823 +0.0 03/31/2026
Alpha Wave Global LP 11.50 3,612,211 +0.0 03/31/2026
FMR Inc 11.45 3,597,784 -2.8 03/31/2026
Versant Venture Management LLC 8.46 2,656,888 +0.0 06/30/2026
BlackRock Inc 6.29 1,976,823 +16.8 03/31/2026
Aberdeen Group PLC 4.93 1,547,883 +33.9 06/30/2026
Millennium Management LLC 4.80 1,508,478 +73.5 06/30/2026
Squarepoint Ops LLC 4.79 1,506,499 +206.3 03/31/2026
Franklin Templeton Inc 3.50 1,100,148 +0.3 03/31/2026

Funds

Funds LENZ
Name Stake (%) Shares Change (%) Date
Fidelity Growth Compy Commingled Pl S 3.77 1,185,611 -28.2 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?